Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2022 - 01 - 24 save search
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
Published: 2022-01-24 (Crawled : 22:00) - biospace.com/
ETNB | $8.59 -3.7% -3.84% 870K
|
Health Technology
|
| O: -2.79%
H: 2.67%
C: -1.44%
bio89 treatment expansion phase 1b trial 100 phase 1 report topline results positive results topline nash phase 2b
CareTrust REIT, Inc. Announces Tax Treatment of 2021 Dividends
Published: 2022-01-24 (Crawled : 15:30) - globenewswire.com
CTRE | $23.81 -0.38% 0.0% 630K
|
Finance
|
| O: -0.52%
H: 0.14%
C: -0.24%
treatment trust
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor
Published: 2022-01-24 (Crawled : 15:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: -3.42%
H: 4.87%
C: 3.98%
ad04 treatment genetic als serotonin-3 order patent opioid biomarkers
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 510K
|
Health Technology
|
| O: -3.0%
H: 11.05%
C: 10.59%
NSTG M | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: -2.39%
H: 10.58%
C: 9.87%
treatment genomic cel lung cancer cancer
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
CDXS | $2.82 -2.76% -2.84% 210K
|
Process Industries
|
| O: -9.93%
H: 7.09%
C: 6.37%
treatment fda rare drug disease rare pediatric disease designation orphan drug designation
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 10.0%
H: 7.27%
C: -1.82%
covid-19 treatment phase 2 trial covid tollovir
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Published: 2022-01-24 (Crawled : 13:30) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -2.11%
H: 2.77%
C: 2.72%
hzn-825 treatment phase 2 fibrosis phase 2b trial therapeutics enroll
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: -9.09%
H: 3.23%
C: -1.13%
lp-184 treatment rare drug disease designation
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
TCRX | News 3 d | $7.39 1.79% 1.76% 91K
|
Professional, Scientific, and T...
|
| O: -1.26%
H: 0.0%
C: -6.82%
tsc-100 new drug treatment fda ema clearance application drug therapeutics fda clearance 100 scan
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 1.39%
H: 6.65%
C: 6.09%
treatment fda drug orphan drug syndros designation
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published: 2022-01-24 (Crawled : 12:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -3.62%
H: 7.66%
C: 6.27%
hpv16 new drug treatment fda clearance solid tumors application hpv drug cel fda clearance positive therapy biotech iot
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
SABS | $4.36 7.54% 730
|
|
| O: -3.74%
H: 14.05%
C: 12.57%
sab-185 covid-19 treatment phase 2 trial therapeutics covid report positive phase 3 iot
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Published: 2022-01-24 (Crawled : 11:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: -6.52%
H: 0.0%
C: -2.93%
treatment trial phase 3 enroll
The Levi’s® 501® Original gets the NFT Treatment
Published: 2022-01-24 (Crawled : 09:00) - levistrauss.com
LEVI | $21.57 -2.22% -0.28% 2.9M
|
Consumer Non-Durables
|
| O: -1.56%
H: 4.96%
C: 4.96%
treatment
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
Published: 2022-01-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval system therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.